Research Topics
| John A KanisSummaryAffiliation: University of Sheffield Country: UK Publications
| Collaborators
|
Detail Information
Publications
A meta-analysis of prior corticosteroid use and fracture riskJohn A Kanis
Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Sheffield, United Kingdom
J Bone Miner Res 19:893-9. 2004..Current and past use of corticosteroids was an important predictor of fracture risk that was independent of prior fracture and BMD...
Optimization of BMD measurements to identify high risk groups for treatment--a test analysisHelena Johansson
Statistician, Romelanda, Sweden
J Bone Miner Res 19:906-13. 2004..These findings need to be validated in other cohorts at different ages and from different regions of the world...
European guidance for the diagnosis and management of osteoporosis in postmenopausal womenJ A Kanis
WHO Collaborating Centre, UK University of Sheffield Medical School, Sheffield, UK
Osteoporos Int 24:23-57. 2013..Guidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk of fractures due to osteoporosis...
The distribution of FRAX(®)-based probabilities in women from JapanJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK
J Bone Miner Metab 30:700-5. 2012..The incorporation of FRAX into assessment guidelines is likely to redirect treatments for osteoporosis from younger women at low risk to elderly women at high fracture risk...
A systematic review of hip fracture incidence and probability of fracture worldwideJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK
Osteoporos Int 23:2239-56. 2012..There was a greater than 10-fold variation in hip fracture risk and fracture probability between countries...
Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosisJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
Bone 27:585-90. 2000..The decrease in relative risk with age is, however, associated with an increase in absolute risk. Thus, for clinical use, the expression of absolute risks may be preferred to relative risks...
Epidemiology of osteoporosis and fracture in menJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Rd, Sheffield, United Kingdom S10 2RX
Calcif Tissue Int 75:90-9. 2004
Interpretation and use of FRAX in clinical practiceJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 22:2395-411. 2011..Its use in fracture risk prediction has strengths, but also limitations of which the clinician should be aware and are the focus of this review..
Pitfalls in the external validation of FRAXJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Osteoporos Int 23:423-31. 2012..Recent studies have evaluated the performance of FRAX® in independent cohorts. The interpretation of most is problematic for reasons summarised in this perspective...
A family history of fracture and fracture risk: a meta-analysisJ A Kanis
Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Sheffield, UK
Bone 35:1029-37. 2004..Its identification on an international basis supports the use of this risk factor in case-finding strategies...
Assessment of fracture riskJohn A Kanis
Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 16:581-9. 2005..Treatment can then be offered to those identified to have a fracture probability greater than an intervention threshold...
The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical DensitometryJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield S10 2DU, UK
Osteoporos Int 16:456-9, discussion 579-80. 2005
Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fractureJ A Kanis
Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Osteoporos Int 16:475-82. 2005....
Assessment of fracture riskJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Eur J Radiol 71:392-7. 2009..Fracture probability rather than BMD alone can be used to fashion strategies for the assessment and treatment of osteoporosis...
Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trialJohn A Kanis
WHO Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
Bone 33:293-300. 2003....
A reappraisal of generic bisphosphonates in osteoporosisJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Osteoporos Int 23:213-21. 2012..The competitive price of generic bisphosphonates has had a marked effect on practice guidelines, but an increasing body of evidence suggests that they have more limited effectiveness than generally assumed...
Excess mortality after hospitalisation for vertebral fractureJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, S10 2RX, Sheffield, UK
Osteoporos Int 15:108-12. 2004..We conclude that a minority of deaths following hospitalization for vertebral fracture are attributable to the fracture itself under the assumptions we used...
Acute and long-term increase in fracture risk after hospitalization for strokeJ Kanis
Center for Metabolic Bone Diseases World Health Organization Collaborating Center, University of Sheffield Medical School UK
Stroke 32:702-6. 2001..The aims of this study were to determine the magnitude of the increase in fracture risk after hospitalization for stroke, and in particular to determine the time course of this risk...
Diagnosis of osteoporosis and assessment of fracture riskJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield S10 2RX, UK
Lancet 359:1929-36. 2002..Many treatments can be provided cost-effectively to men and women if hip fracture probability over 10 years ranges from 2% to 10% dependent on age...
The components of excess mortality after hip fractureJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Bone 32:468-73. 2003..Hip fracture was a more common cause for mortality than pancreatic or stomach cancer. Thus, interventions that decreased hip fracture rate by, say, 50% would avoid 0.75% or more of all deaths...
Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAXEugene V McCloskey
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom
J Bone Miner Res 27:1480-6. 2012..Denosumab significantly decreased the risk of clinical osteoporotic fractures in postmenopausal women. Overall, the efficacy of denosumab was greater in those at moderate to high risk of fracture as assessed by FRAX...
FRAX(®) Clinical Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development ConferenceEugene V McCloskey
University of Sheffield, Sheffield, UK
J Clin Densitom 14:181-3. 2011..This synthesis was presented to the expert panel and constitutes the data on which the subsequent Official Positions are predicated. A summary of the Clinical Task Force composition and charge is presented here...
Alcohol intake as a risk factor for fractureJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 16:737-42. 2005..We conclude that reported intake of alcohol confers a risk of some importance beyond that explained by BMD. The validation of this risk factor on an international basis permits its use in case-finding strategies...
Intervention thresholds for osteoporosis in men and women: a study based on data from SwedenJohn A Kanis
Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 16:6-14. 2005....
A meta-analysis of milk intake and fracture risk: low utility for case findingJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 16:799-804. 2005..We conclude that a self-reported low intake of milk is not associated with any marked increase in fracture risk and that the use of this risk indicator is of little or no value in case-finding strategies...
Vertebral fracture assessment (VFA) with a densitometer predicts future fractures in elderly women unselected for osteoporosisEugene V McCloskey
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom
J Bone Miner Res 23:1561-8. 2008..Having multiple vertebral fractures was associated with greater risk of incident osteoporotic fractures and hip fractures...
A reference standard for the description of osteoporosisJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK
Bone 42:467-75. 2008..5 SD or more below the average for young adult women. The adoption of DXA as a reference standard provides a platform on which the performance characteristics of less well established and new methodologies can be compared...
Intervention thresholds for osteoporosis in the UKJohn A Kanis
Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Sheffield, UK
Bone 36:22-32. 2005....
The perspective of the international osteoporosis foundation on the official positions of the international society for clinical densitometryJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, S10 2DU, Sheffield, UK
J Clin Densitom 8:145-7. 2005
Fracture risk assessmentEugene McCloskey
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
Clin Biochem 45:887-93. 2012..Notwithstanding, the present models provide an aid to enhance patient assessment by the integration of clinical risk factors alone and/or in combination with BMD...
A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAXJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield, UK
Bone 47:729-35. 2010..There was no significant effect on non-vertebral fracture...
FRAX updates 2012Eugene McCloskey
Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK
Curr Opin Rheumatol 24:554-60. 2012..This brief review addresses the development of FRAX since then and describes some of the issues that continue to be discussed as FRAX plays an increasing role in clinical practice...
Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAXJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK
Bone 44:1049-54. 2009..No significant effect was noted on the risk of clinical fractures, but fracture risk reduction was reported in a post hoc subgroup analysis in a high risk group categorised on the basis of BMD and prior fracture...
International variations in hip fracture probabilities: implications for risk assessmentJohn A Kanis
WHO Collaborating Center for Metabolic Bone Diseases, University of Sheffield Medical School, United Kingdom
J Bone Miner Res 17:1237-44. 2002..The categorization of hip fracture probabilities can be used to adjust intervention thresholds based on age, sex, and relative risk from a reference population such as Sweden...
From relative risk to absolute fracture risk calculation: the FRAX algorithmEugene V McCloskey
World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sorby Wing, Northern General Hospital, Herries Road, Sheffield S5 7AU, United Kingdom
Curr Osteoporos Rep 7:77-83. 2009..Notwithstanding, the present models provide an aid to enhance patient assessment by the integration of clinical risk factors alone and/or in combination with BMD. This article describes the steps undertaken in the development of FRAX...
FRAX(®) with and without bone mineral densityJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Calcif Tissue Int 90:1-13. 2012....
Approaches to the targeting of treatment for osteoporosisJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
Nat Rev Rheumatol 5:425-31. 2009..The tool increases sensitivity without trading specificity, and is now being used in the reappraisal of clinical guidelines...
FRAX and its applications to clinical practiceJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
Bone 44:734-43. 2009....
Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized studyEugene V McCloskey
Northern General Hospital, Sheffield, UK
J Bone Miner Res 22:135-41. 2007..The effect occurred in the absence of systematic calcium and vitamin D supplementation and was observed across a wide range of BMDs...
Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year studyEugene McCloskey
Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom
J Bone Miner Res 19:728-36. 2004..The incidence of vertebral fractures was significantly reduced by 46%. The effect was not modified by the underlying cause of osteoporosis or other baseline factors including bone mineral density, QUS, weight, and smoking...
Official Positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®Eugene V McCloskey
Academic Unit of Bone Metabolism, University of Sheffield, Sheffield S5 7AU, UK
J Clin Densitom 14:220-2. 2011..More research is clearly required to address these deficiencies before biochemical markers might contribute a useful independent risk factor for inclusion in FRAX(®)...
Assessing the impact of osteoporosis on the burden of hip fracturesAnders Oden
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Calcif Tissue Int 92:42-9. 2013..We conclude that osteoporosis accounts for approximately half of all hip fractures. Strategies to prevent osteoporosis could save up to 50 % of all hip fractures...
Evidence from data searches and life-table analyses for gender-related differences in absolute risk of hip fracture after Colles' or spine fracture: Colles' fracture as an early and sensitive marker of skeletal fragility in white menPatrick Haentjens
Department of Orthopaedics and Traumatology, Vrije Universiteit Brussel, Brussels, Belgium
J Bone Miner Res 19:1933-44. 2004..The gender-related differences reported in this analysis should be taken into account when designing screening and treatment strategies for prevention of hip fracture in men...
Association between vertebral fracture and increased mortality in osteoporotic patientsTarja Jalava
Leiras, Helsinki, Finland
J Bone Miner Res 18:1254-60. 2003..4; 95% CI, 0.93, 6.23). CONCLUSIONS: Prevalent vertebral fractures in osteoporotic patients are associated with increased mortality. Other known predictors of mortality can explain a significant proportion of the excess risk...
Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS)Mark Lunt
ARC Epidemiology Unit, University of Manchester, Manchester, UK
Bone 33:505-13. 2003..0 (95% CI;2.6, 6.0)). In summary, the risk of a subsequent vertebral fracture in individuals with preexisting deformities is importantly influenced by the characteristics of these deformities...
The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risksTjeerd Peter van Staa
Utrecht University, Utrecht, The Netherlands
Value Health 10:348-57. 2007..A pharmaco-economic model that used individualized risks for fractures was developed in order to take into account patient heterogeneity...
Predictive value of BMD for hip and other fracturesOlof Johnell
Department of Orthopaedics, Malmo University Hospital, Malmo, Sweden
J Bone Miner Res 20:1185-94. 2005..Its validation on an international basis permits its use in case finding strategies. Its use should, however, take account of the variations in predictive value with age and BMD...
Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) StudyOlof Johnell
Department of Orthopaedics, , Malm, Sweden
J Bone Miner Res 19:764-72. 2004..006) and lower LS BMD values (p = 0.008) at baseline. These data suggest that the efficacy of raloxifene in reducing vertebral fractures is largely independent of the presence of clinical risk factors for osteoporotic fractures...
Risk factors for incident vertebral fractures in men and women: the Rotterdam StudyMarjolein van der Klift
Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
J Bone Miner Res 19:1172-80. 2004..In women, early menopause, current smoking, and walking aid use are additional independent risk factors for incident vertebral fractures...
The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approachChris De Laet
Department of Public Health, Erasmus University Medical Center, PO Box 1738, 3000 DR Rotterdam, The Netherlands
Osteoporos Int 16:313-8. 2005..Case-finding strategies that combine clinical risk indicators with BMD have increased efficiency, while having a modest impact on the number of individuals requiring treatment. Therefore, the cost-effectiveness is enhanced...
Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE studyFredrik Borgstrom
Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
Pharmacoeconomics 22:1153-65. 2004..The Multiple Outcomes of Raloxifene Evaluation (MORE) study showed that treatment with raloxifene reduces the risk of vertebral fracture and breast cancer in postmenopausal women with osteoporosis...
Potential impact of osteoporosis treatment on hip fracture trendsL Joseph Melton
J Bone Miner Res 20:895-7. 2005
Incidence rates and life-time risk of hip fractures in Mexicans over 50 years of age: a population-based studyPatricia Clark
Clinical Epidemiology Unit, CMN Siglo XXI IMSS Faculty of Medicine, UNAM, Mexico City, Mexico
Osteoporos Int 16:2025-30. 2005..5% in Mexican women and 3.8% in Mexican men. We conclude that hip fractures are an important health problem in Mexico and that Mexican health authorities should consider public health programs to prevent hip fractures...
Assessment of the 10-year probability of osteoporotic hip fracture combining clinical risk factors and heel bone ultrasound: the EPISEM prospective cohort of 12,958 elderly womenDidier Hans
Nuclear Medicine Division, Geneva University Hospital, Geneva, Switzerland
J Bone Miner Res 23:1045-51. 2008..9% to 26.6% and from 52.6% to 70.5% for SI Z-scores of +2 and -3, respectively. The combined use of CRFs and QUS SI is a promising tool to assess hip fracture probability in elderly women, especially when access to DXA is limited...
Herbert Andre Fleisch, MD : 22 July 1933-15 May 2007T John Martin
Osteoporos Int 18:1019-21. 2007
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancerTrevor Powles
Royal Marsden National Health Service Trust, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
J Clin Oncol 20:3219-24. 2002..Given to patients with primary breast cancer, clodronate might reduce the subsequent incidence of bone metastases...
Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF studyYu Z Bagger
Center for Clinical and Basic Research A S, Ballerup, Denmark
Bone 34:728-35. 2004..In conclusion, limited HRT administered in the early postmenopausal years offers long-lasting benefits for the prevention of postmenopausal bone loss and osteoporotic fracture...
Critical issues in translational and clinical research for the study of new technologies to enhance bone repairJörg Goldhahn
Department of Research, Schulthess Klinik, Lengghalde 2, Zurich 8008, Switzerland
J Bone Joint Surg Am 90:43-7. 2008..The guidelines should be harmonized between European and American regulatory authorities to ensure comparability of results of studies and to foster global harmonization of regulatory requirements...
Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trialIngrid Lekander
i3 Innovus, Vasagatan 38, SE 111 20 Stockholm, Sweden
Bone 42:294-306. 2008..The purpose of the study was to assess the cost effectiveness of hormone therapy (HT) for postmenopausal women without menopausal symptoms at an increased risk of fracture in Sweden, the UK and the US...
The cost-effectiveness of alendronate in the management of osteoporosisJohn A Kanis
Bone 42:4-15. 2008..We conclude that alendronate is a cost-effective agent for the prevention and treatment of fractures associated with osteoporosis. These findings, suitable for informing practice guidance, contrast with recent appraisals from NICE...
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosisJörg Goldhahn
Schulthess Clinic Zurich and Clinical Priority Program Fracture Fixation in Osteoporotic, Bone of AO Foundation, Davos, Switzerland
Bone 43:343-7. 2008..The study design should be randomized, parallel, double-blind, and placebo-controlled, and all fracture subjects should receive a standardized method of fracture fixation, defined as Standard of Care...
